News

Veeva price target lowered to $250 from $260 at KeyBanc
KeyBanc lowered the firm’s price target on Veeva (VEEV) to $250 from $260 and keeps an Overweight rating on the shares. Into Q1 earnings, the ...
pharmaphorum1d
Why pharma isn’t yet achieving digital excellence, and how it can get there
To thrive in this environment, pharma needs to move from ad-hoc and reactionary digital transformation to long-term ‘digital excellence’, says Veeva’s Sebastien Noel. COVID has seen pharma ...